# BreastScreen Australia NAS Measure and Protocol Concise Descriptors and Acronyms

## Purpose

The purpose of this document is to provide:

* Concise descriptors for BreastScreen Australia (BSA) [NAS Measures](#_NAS_Measure_Concise);
* Concise descriptors for BSA [Protocols](#_Protocol_Concise_Descriptors); and
* A list of [acronyms](#_BreastScreen_Australia_List) for commonly used terms in the BSA program.

These concise descriptors and acronyms can be used by BSA internal stakeholders in:

* Internal NQMC documentation;
* Meeting papers;
* Accreditation submissions;
* Correspondence within the program (with jurisdictions, the Program Management Group (PMG) or Department of Health);
* Internal email communications; and
* National Surveyor documentation (where appropriate).

### NAS Measure Concise Descriptors

The NQMC established concise descriptors for NAS Measures in 2016 for use in internal BSA documentation and correspondence. The following table contains concise descriptors for NAS Measures.

**Note:** The NAS Measure concise descriptors are for convenience and are not intended to be self-explanatory. Please refer to the full NAS and/or Data Dictionary for definitions and detail.

| *Standard* | *Level* | *NAS #* | *NAS Description (short name)* | *Type* |
| --- | --- | --- | --- | --- |
| *Access/Participation* | *2* | *1.1.1(a)* | *Partic 50-74 last 24 months* | *Monitor* |
| *Access/Participation* | *2* | *1.1.1(b)* | *Partic 50-69 last 24 months (≥70%)* | *Benchmark* |
| *Access/Participation* | *2* | *1.1.2(a)* | *Rescreen R1 50-72 in 27 months* | *Monitor* |
| *Access/Participation* | *2* | *1.1.2(b)* | *Rescreen R1 50-67 in 27 months (≥75%)* | *Benchmark* |
| *Access/Participation* | *2* | *1.1.3(a)* | *Rescreen R2+ 50-72 in 27 months* | *Monitor* |
| *Access/Participation* | *2* | *1.1.3(b)* | *Rescreen R2+ 50-67 in 27 months (≥90%)* | *Benchmark* |
| *Access/Participation* | *2* | *1.2.1(a)(i)* | *Partic 50-74 special groups - indig* | *Monitor* |
| *Access/Participation* | *2* | *1.2.1(a)(ii)* | *Partic 50-74 special groups - CALD* | *Monitor* |
| *Access/Participation* | *2* | *1.2.1(a)(iii)* | *Partic 50-74 special groups - remote* | *Monitor* |
| *Access/Participation* | *2* | *1.2.1(a)(iv)* | *Partic 50-74 special groups - SES* | *Monitor* |
| *Access/Participation* | *2* | *1.2.1(b)(i)* | *Partic 50-69 special groups - indig* | *Monitor* |
| *Access/Participation* | *2* | *1.2.1(b)(ii)* | *Partic 50-69 special groups - CALD* | *Monitor* |
| *Access/Participation* | *2* | *1.2.1(b)(iii)* | *Partic 50-69 special groups - remote* | *Monitor* |
| *Access/Participation* | *2* | *1.2.1(b)(iv)* | *Partic 50-69 special groups - SES* | *Monitor* |
| *Access/Participation* | *3* | *1.2.2(a)* | *1.2.2(a) Partic all women 40-49 and 75+* | *Monitor* |
| *Access/Participation* | *3* | *1.2.2(b)* | *Partic all women recalled 40-49 and 75+* | *Monitor* |
| *Cancer Detection* | *1* | *2.1.1(a)* | *Cancer invasive R1 50-74* | *Monitor* |
| *Cancer Detection* | *1* | *2.1.1(b)* | *Cancer invasive R1 50-69 (≥50/10k)* | *Benchmark* |
| *Cancer Detection* | *1* | *2.1.2(a)* | *Cancer invasive R2+ 50-74* | *Monitor* |
| *Cancer Detection* | *1* | *2.1.2(b)* | *Cancer invasive R2+ 50-69 (≥35/10k)* | *Benchmark* |
| *Cancer Detection* | *1* | *2.1.3(a)* | *Cancer small R1 50-74* | *Monitor* |
| *Cancer Detection* | *1* | *2.1.3(b)* | *Cancer small R2+ 50-74* | *Monitor* |
| *Cancer Detection* | *1* | *2.1.3(c)* | *Cancer small 50-69 (≥25/10K)* | *Benchmark* |
| *Cancer Detection* | *2* | *2.1.4(a)* | *Cancer invasive annual women 50-74* | *Monitor* |
| *Cancer Detection* | *2* | *2.1.4(b)* | *Cancer small annual women 50-74* | *Monitor* |
| *Cancer Detection* | *2* | *2.1.4(c)* | *Cancer invasive annual women 40-49* | *Monitor* |
| *Cancer Detection* | *2* | *2.1.5* | *Cancer invasive 40-49 and 75+* | *Monitor* |
| *Cancer Detection* | *2* | *2.1.6* | *Cancer invasive small (≤ 15mm) 40-49 and 75+* | *Monitor* |
| *Cancer Detection* | *2* | *2.2.1(a)* | *DCIS R1 50-74 (mon)* | *Monitor* |
| *Cancer Detection* | *2* | *2.2.1(b)* | *DCIS R1 50-69 (≥12/10k)* | *Benchmark* |
| *Cancer Detection* | *2* | *2.2.2(a)* | *DCIS R2+ 50-74* | *Monitor* |
| *Cancer Detection* | *2* | *2.2.2(b)* | *DCIS R2+ 50-69 (≥7/10k)* | *Benchmark* |
| *Cancer Detection* | *3* | *2.2.3* | *DCIS annual women 50-74* | *Monitor* |
| *Cancer Detection* | *2* | *2.2.4* | *DCIS 40-49 and 75+* | *Monitor* |
| *Cancer Detection* | *2* | *2.3.1(a)* | *Interval cancer 1st year 50-74* | *Monitor* |
| *Cancer Detection* | *2* | *2.3.1(b)* | *Interval cancer 1st year 50-69 (<7.5 per 10k)* | *Benchmark* |
| *Cancer Detection* | *2* | *2.3.1(c)* | *Interval invasive breast cancer 1st year 40-49 and 75+* | *Monitor* |
| *Cancer Detection* | *2* | *2.3.2(a)* | *Interval cancer 2nd year 50-74* | *Monitor* |
| *Cancer Detection* | *2* | *2.3.2(b)* | *Interval cancer 2nd year 50-69 (≤15 per 10k)* | *Benchmark* |
| *Cancer Detection* | *2* | *2.3.2(c)* | *Interval cancer 2nd year 40-49 and 75+* | *Monitor* |
| *Cancer Detection* | *2* | *2.4.1* | *Reads by reader (>2000)* | *Benchmark* |
| *Cancer Detection* | *3* | *2.5.1* | *Women with up to four images* | *Monitor* |
| *Cancer Detection* | *3* | *2.5.2* | *Tech repeat rate (≤2%)* | *Benchmark* |
| *Cancer Detection* | *2* | *2.6.1(a)* | *Annual screening 50-74* | *Monitor* |
| *Cancer Detection* | *2* | *2.6.1(b)* | *Annual screening 50-69 (≤10%)* | *Benchmark* |
| *Cancer Detection* | *3* | *2.6.2* | *Annual screening 40-49, 75+* | *Monitor* |
| *Cancer Detection* | *2* | *2.6.3(a)* | *Recall R1 50-74* | *Monitor* |
| *Cancer Detection* | *2* | *2.6.3(b)* | *Recall R1 50-69 (<10%)* | *Benchmark* |
| *Cancer Detection* | *2* | *2.6.3(c)* | *Recall R1 40-49 and 75+* | *Monitor* |
| *Cancer Detection* | *2* | *2.6.4(a)* | *Recall R2+ 50-74* | *Monitor* |
| *Cancer Detection* | *2* | *2.6.4(b)* | *Recall R2+ 50-69 (<5%)* | *Benchmark* |
| *Cancer Detection* | *2* | *2.6.4(c)*  | *Recall R2+ 40-49 and 75+* | *Monitor* |
| *Cancer Detection* | *2* | *2.6.5* | *Recall PPV R1 50-74* | *Monitor* |
| *Cancer Detection* | *2* | *2.6.6* | *Recall PPV R2+ 50-74* | *Monitor* |
| *Cancer Detection* | *2* | *2.6.7* | *Early review (<0.2%)* | *Benchmark* |
| *Assessment* | *2* | *3.1.1* | *Needle biopsies, benign (<5%)* | *Benchmark* |
| *Assessment* | *2* | *3.1.2(a)* | *Benign lesions, false positive (0%)* | *Benchmark* |
| *Assessment* | *2* | *3.1.2(b)* | *False positive root cause analysis (100%)* | *Benchmark* |
| *Assessment* | *2* | *3.1.3* | *Absolute sensitivity of biopsy (>90%)* | *Benchmark* |
| *Assessment* | *1* | *3.1.4* | *Open biopsies benign R1 (≤0.35%)* | *Benchmark* |
| *Assessment* | *1* | *3.1.5* | *Open biopsies benign R2+ (≤0.16%)* | *Benchmark* |
| *Assessment* | *3* | *3.1.6* | *Specimen imaging (100%)* | *Benchmark* |
| *Assessment* | *1* | *3.1.7* | *Lesions identified first excision (≥95%)* | *Benchmark* |
| *Assessment* | *1* | *3.1.8(a)* | *Diagnosis without excision (≥85%)* | *Benchmark* |
| *Assessment* | *1* | *3.1.8(b)* | *Diagnosis without excision, DCIS vs invasive* | *Monitor* |
| *Timeliness* | *2* | *4.1.1(a)* | *Time to screening 28 days 50-74 (≥90%)* | *Benchmark* |
| *Timeliness* | *2* | *4.1.1(b)* | *Time to screening, days to 90% 50-74* | *Monitor* |
| *Timeliness* | *2* | *4.1.2* | *Time to results 14 days (>90%)* | *Benchmark* |
| *Timeliness* | *1* | *4.2.1(a)* | *Time to assessment 28 days (≥90%)* | *Benchmark* |
| *Timeliness* | *1* | *4.2.1(b)* | *Time to assessment, days to 90%* | *Monitor* |
| *Timeliness* | *1* | *4.2.1(c)* | *Time to assessment, offered in 28 days* | *Monitor* |
| *Timeliness* | *2* | *4.2.2* | *Results at first assessment visit (≥95%)* | *Benchmark* |
| *Timeliness* | *2* | *4.2.3* | *Assessment visits no more than two (≥95%)* | *Benchmark* |
| *Timeliness* | *2* | *4.2.4* | *Biopsy verbal results 7 days (≥85%)* | *Benchmark* |
| *Timeliness* | *2* | *4.2.5* | *Assessment complete 15 days (>95%)* | *Benchmark* |
| *Timeliness* | *2* | *4.2.6* | *Assessment results 14 days (100%)* | *Benchmark* |
| *Data Management* | *2* | *5.1.1* | *Histo info received (≥95%)* | *Benchmark* |
| *Data Management* | *3* | *5.1.2* | *Treatment info received (≥95%)* | *Benchmark* |

### Protocol Concise Descriptors

The NQMC established concise descriptors for Protocols in 2018 for use in internal BSA documentation and correspondence. The following table contains concise descriptors for NAS Protocols

The following table contains equivalent concise descriptors for Protocols.

**Note:** As with those for NAS Measures, the concise descriptors are for convenience and are not intended to be self-explanatory. Please refer to the full Protocol and/or Data Dictionary for definitions and detail.

| *Standard* | *Protocol (short name)* |
| --- | --- |
| *Access/Participation* | *1.1: Recruitment, invitations and equitable participation.* |
| *Cancer Detection* | *2.1: 2.1: Resolution of discordance reading outcomes.* |
| *Cancer Detection* | *2.2: ALARA, standard views & deviation, breast prosthesis.* |
| *Cancer Detection* | *2.3: 2.3: PGMI Evaluation.* |
| *Cancer Detection* | *2.4: P or G rating ≥50%.*  |
| *Cancer Detection* | *2.5: Image ID RANZCR compliance.* |
| *Cancer Detection* | *2.6: Identify & review interval cancers.* |
| *Cancer Detection* | *2.7: Reader performance and feedback.* |
| *Cancer Detection* | *2.8: Review & address reader performance.* |
| *Cancer Detection* | *2.9: Management of breast symptoms.* |
| *Assessment* | *3.1: MDT expertise.* |
| *Assessment* | *3.2: MDT correlations.* |
| *Assessment* | *3.3: Percutaneous needle biopsy radiologist & MDT member review.* |
| *Assessment* | *3.4: Correlation lesions surgery detected through screening.* |
| *Assessment* | *3.5: Discordance assessment & post-surgical follow up.* |
| *Assessment* | *3.6: Screening staff with assessment unit.* |
| *Assessment* | *3.7: Evaluation of women recalled to assessment.* |
| *Data Management* | *5.1: Conform data dictionary.* |
| *Data Management* | *5.2: Data quality control throughout screening & assessment.* |
| *Data Management* | *5.3: Staff instructed to ensure data quality.* |
| *Data Management* | *5.4: Security, accuracy, integrity & management of data.* |
| *Data Management* | *5.5: File tracking system.* |
| *Data Management* | *5.6: Unique identifier.* |
| *Data Management* | *5.7: Records identifiable to health professional.* |
| *Data Management* | *5.8: Records retention & storage.* |
| *Data Management* | *5.9: Disaster recovery PACS & BIS.* |
| *Data Management* | *5.10: Develop & maintain high quality ICT systems.* |
| *Client Focus* | *6.1: Information available to women throughout pathway.* |
| *Client Focus* | *6.2: Information provided on waiting times along pathway* |
| *Client Focus* | *6.3: Provision of results by medical practitioner, counsellor support.* |
| *Client Focus* | *6.4: Access to own records, including copies of images.* |
| *Client Focus* | *6.5: Strategy to encourage key stakeholder participation* |
| *Client Focus* | *6.6: Seek feedback about acceptability and appropriateness of screening and assessment.* |
| *Client Focus* | *6.7: Opportunity to ask questions before consent* |
| *Client Focus* | *6.8: Consent records that information given and understood.* |
| *Client Focus* | *6.9: Consent obtained for screening, assessment, data sourcing and release.* |
| *Client Focus* | *6.10: Option of referral to a clinic or returning to GP* |
| *Client Focus* | *6.11: Protocol for referral for subsequent management* |
| *Client Focus* | *6.12: Women diagnosed are advised of future status in Program.* |
| *Governance & Management* | *7.1: Position descriptions* |
| *Governance & Management* | *7.2: Expertise, experience and training standards in Appendix C.* |
| *Governance & Management* | *7.3: Staff trained policies, protocols and procedures* |
| *Governance & Management* | *7.4: Regular clinical breast specific professional development activities* |
| *Governance & Management* | *7.5: Designated Pathologist RCPA QA*  |
| *Governance & Management* | *7.6: Screening and assessment units BSA identifiable and resourced.* |
| *Governance & Management* | *7.7: Review, assess and implement a detailed QIP* |
| *Governance & Management* | *7.8: Research projects Ethics Committee approval* |
| *Governance & Management* | *7.9: Management or advisory structure key stakeholder representation* |
| *Governance & Management* | *7.10: Where Service and SCU are separate, contract detailing responsibilities and accountabilities.* |
| *Governance & Management* | *7.11: Financial management systems* |
| *Governance & Management* | *7.12: Infection control processes.*  |
| *Governance & Management* | *7.13: Incident management and open disclosure.* |
| *Governance & Management* | *7.14: Policy, Protocols and Procedures Manual maintained* |
| *Governance & Management* | *7.15: Policy, Protocols and Procedures are implemented, reviewed and improved.*  |
| *Governance & Management* | *7.16: Audit schedule policies, protocols and procedures* |
| *Governance & Management* | *7.17: Appropriate equipment*  |
| *Governance & Management* | *7.18: Radiation protection regulations.* |
| *Governance & Management* | *77.19 Breast imaging systems meet specifications, quality control, Appendices D, E, F & RANZCR imaging Standards.* |
| *Governance & Management* | *7.20: Preventative maintenance and repair of imaging equipment* |
| *Governance & Management* | *7.21: Pathology laboratories RCPA NATA accreditation* |
| *Governance & Management* | *7.22: New technologies* |

### BreastScreen Australia List of Acronyms

Given the familiarity of BSA stakeholders with a number of key acronyms used frequently within the program, the acronyms contained in the following table can be used within the BSA Program. This would remove the requirement to include full explanations of each acronym every time they are used.

|  |  |
| --- | --- |
| Acronym | Explanation |
| ADR | Annual Data Report  |
| ATSI  | Aboriginal and Torres Strait Islander  |
| BIS  | Business Information System  |
| BSA  | BreastScreen Australia  |
| CALD  | Culturally and Linguistically Diverse  |
| CQI  | Continuous Quality Improvement  |
| DGMA  | Data Governance and Management Assessment  |
| MDM/T  | Multi-Disciplinary Meeting/Team  |
| NAF  | NAS Accountability Framework  |
| NAS  | National Accreditation Standards  |
| NQMC  | National Quality Management Committee  |
| PACS  | Picture Archiving and Communication System  |
| PGMI  | Perfect, Good, Moderate, Inadequate  |
| PMC  | Protocol Management Checklist  |
| QA  | Quality Assurance  |
| QI  | Quality Improvement  |
| QIP  | Quality Improvement Plan  |
| SAS (NSW) | Screening & Assessment Service |
| SCU  | State Coordination Unit  |
| SQC | State Quality Committee |